|
gptkbp:instanceOf
|
gptkb:hedge_fund
|
|
gptkbp:assetsUnderManagement
|
over $15 billion (as of 2023)
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:foundedBy
|
gptkb:Felix_Baker
gptkb:Julian_Baker
|
|
gptkbp:foundedYear
|
2000
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Baker Bros. Advisors
|
|
gptkbp:industry
|
investment management
biotechnology investments
|
|
gptkbp:investedIn
|
long-term growth in biotechnology
|
|
gptkbp:keyPerson
|
gptkb:Felix_Baker
gptkb:Julian_Baker
|
|
gptkbp:notableFor
|
gptkb:Scholar_Rock
gptkb:Mirati_Therapeutics
gptkb:Turning_Point_Therapeutics
gptkb:Incyte
gptkb:Cytokinetics
gptkb:Seagen
gptkb:MorphoSys
gptkb:C4_Therapeutics
gptkb:BeiGene
gptkb:ACADIA_Pharmaceuticals
gptkb:AnaptysBio
gptkb:BioCryst_Pharmaceuticals
gptkb:ImmunoGen
gptkb:Kiniksa_Pharmaceuticals
gptkb:Kodiak_Sciences
gptkb:Replimune_Group
gptkb:Xencor
gptkb:Zymeworks
gptkb:argenx
biotech sector focus
|
|
gptkbp:regulatoryFiling
|
gptkb:SEC_Form_13F
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.bakerbrosadvisors.com/
|
|
gptkbp:bfsParent
|
gptkb:Felix_Baker
|
|
gptkbp:bfsLayer
|
6
|